Humira costs $6,922/month in the U.S. and $1,362 in the UK. Insulin costs $300 in the U.S. and $30 in Canada. Here's why drug prices vary so dramatically across countries — and who's right.
Educational content only — not personalized financial, legal, or tax advice.
Humira (adalimumab), AbbVie's blockbuster rheumatoid arthritis drug, cost approximately $6,922 per month in the U.S. in 2022. In the UK: approximately $1,362. In Switzerland: $1,791. In Japan: $1,870. The drug is the same molecule, made by the same company, performing the same function.
Insulin, which has been off-patent for decades, cost approximately $300/vial in the U.S. before congressional action in 2022 capped Medicare and Medicaid insulin prices at $35/month. The same insulin in Canada: approximately $30-40/vial. Germany: $30-50/vial.
These are not anomalies. U.S. drug prices are systematically 2-4x the prices in other wealthy countries for brand-name drugs. For generic drugs, U.S. prices are often comparable or lower than international prices — the U.S. generic market is highly competitive.
This connects to why U.S. healthcare costs 2x other countries and the systemic pricing structure](/article/why-u-s-healthcare-costs-2x-other-countries) and to pharmaceutical patents and the 20-year clock that enables these pricing dynamics.
Every wealthy country except the United States uses some form of government negotiation, reference pricing, or health technology assessment to control drug prices:
UK (NICE): The National Institute for Health and Care Excellence evaluates drugs' cost-effectiveness — how much a drug costs per quality-adjusted life year (QALY) gained. Drugs above approximately £30,000 per QALY are typically not approved for NHS coverage. This benchmark gives NICE hard negotiating leverage.
Germany (AMNOG): Pharmaceutical companies launch drugs at their own prices. The Federal Joint Committee assesses the drug's 'added benefit' over existing therapies within 12 months. Prices are then negotiated with the national payer based on the added benefit assessment. Drugs with no demonstrated added benefit are priced at reference drug level.
Canada: Provincial formularies negotiate prices independently. The Patented Medicine Prices Review Board (PMPRB) historically capped prices at the median of seven reference countries. Canada's prices average approximately 40-55% of U.S. prices for brand-name drugs.
Reference pricing: Many countries link their drug prices to an average of prices in a basket of other countries. This creates international price interdependence — a low price in one country can pull down prices in countries that reference it.
The U.S. historically prohibited Medicare from negotiating drug prices directly — the 2003 Medicare Part D legislation explicitly banned negotiation, a provision that became known as the 'non-interference clause.' The pharmaceutical industry lobbied intensively for this provision.
The Inflation Reduction Act (2022) changed this for the first time: Medicare can now negotiate prices for a small number of high-spend, off-patent-eligible drugs. The first ten drugs were selected in 2023, with negotiated prices taking effect in 2026. The IRA process is limited, but it's the first crack in the non-negotiation framework.
Why pharmaceutical companies accept lower prices in other countries but not the U.S.: the marginal cost of producing drugs is very low — once R&D is recovered, any price above marginal production cost is profitable. If European regulators cap prices at $200 for a drug that costs $5 to produce, the company still profits on European sales. U.S. prices implicitly cross-subsidize R&D recovery that allows international price acceptance.
Pharmaceutical companies argue (with some validity) that U.S. high prices fund the R&D that produces drugs that benefit global patients. The U.S. accounts for approximately 40-45% of global pharmaceutical revenue but represents only 4% of the world's population — American patients are heavily cross-subsidizing global drug access.
Biopharmaceutical R&D costs approximately $2.5-3 billion per approved drug (including failed compounds). High U.S. prices are what makes that investment return positive. The counterargument: even at dramatically lower prices, pharma returns would be substantial; and significant R&D is funded by NIH (government) rather than industry.